Please login to the form below
Duchenne muscular distrophy
This page shows the latest Duchenne muscular distrophy news and features for those working in and with pharma, biotech and healthcare.
NICE backs PTC's muscular dystrophy drug Translarna
Duchenne muscular dystrophy (DMD) patients and their families have welcomed a decision by NICE making PTC Therapeutics' Translarna available on the NHS. ... The Muscular Dystrophy UK charity described the decision as 'history in the making', and welcomed
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
Bedrock Group
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
